Brief: Eledon Pharmaceuticals Announces Dosing Of 10Th Patient In Ongoing Phase 1B Trial Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation
16/08/2023 12:31
Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PHARMACEUTICALS ANNOUNCES DOSING OF 10TH PATIENT IN
ONGOING PHASE 1B TRIAL EVALUATING TEGOPRUBART IN PATIENTS
UNDERGOING KIDNEY TRANSPLANTATION
* ELEDON PHARMACEUTICALS- TO REPORT UPDATED INTERIM CLINICAL
DATA
FROM ONGOING PHASE 1B TRIAL OF TEGOPRUBART IN KIDNEY
TRANSPLANTATION IN NOV 2023
Source text for Eikon: ID:nGNX8yKZ8d
Further company coverage: ELDN.O
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial